Major cancer trial cancelled before starting
NCT ID NCT06585969
Summary
This international study was designed to compare two different drug strategies for controlling advanced breast cancer that has spread. It planned to enroll women with a specific type of ER-positive, HER2-low cancer to see if a newer drug (trastuzumab deruxtecan) works better than the current standard drug combination at delaying cancer growth. The trial was withdrawn before any participants were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.